<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02895737</url>
  </required_header>
  <id_info>
    <org_study_id>290/16s</org_study_id>
    <nct_id>NCT02895737</nct_id>
  </id_info>
  <brief_title>PROTECT TAVI - Prospective Randomized Outcome Study in TAVI Patients Undergoing Periprocedural Embolic Cerebral Protection With the Sentinel™ Device</brief_title>
  <acronym>PROTECT</acronym>
  <official_title>PROTECT TAVI - Prospective Randomized Outcome Study in TAVI Patients Undergoing Periprocedural Embolic Cerebral Protection With the Sentinel™ Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <brief_summary>
    <textblock>
      This prospective, randomized study was designed to analyse the difference of cerebral&#xD;
      embolization in patients undergoing transcatheter aortic valve implantation with&#xD;
      balloon-expandable vs. self-expandable valves by using a cerebral protection system&#xD;
      (Sentinel™ Device).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 28, 2016</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total new lesion volume in protected brain regions detected by Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>Day 2-4 post-procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of new cerebral lesions detected by MRI</measure>
    <time_frame>Day 2-4 post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of clinical stroke and/or neurocognitive dysfunction as assessed by neurological and neurocognitive assessments</measure>
    <time_frame>Day 2-4 post-procedure; 6 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Outcome according to the VARC 2 criteria</measure>
    <time_frame>from operation until hospital discharge; 30-days, 6-months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">328</enrollment>
  <condition>Cerebral Embolization During TAVI Using Balloon-expandable vs. Self-expandable Valves</condition>
  <arm_group>
    <arm_group_label>balloon-expandable TAVI without cerebral protection</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient receives a balloon-expandable transcatheter aortic valve replacement without cerebral protection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>balloon-expandable TAVI with cerebral protection</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient receives a balloon-expandable transcatheter aortic valve replacement with cerebral protection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>self-expandable TAVI without cerebral protection</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient receives a self-expandable transcatheter aortic valve replacement without cerebral protection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>self-expandable TAVI with cerebral protection</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient receives a self-expandable transcatheter aortic valve replacement with cerebral protection</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TAVI: Edwards SAPIEN 3, Edwards Lifesciences, Edwards Sapien Ultra</intervention_name>
    <arm_group_label>balloon-expandable TAVI without cerebral protection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TAVI: Edwards SAPIEN 3, Edwards Lifesciences, Edwards Sapien Ultra; Sentinel™ Cerebral Protection Systems</intervention_name>
    <arm_group_label>balloon-expandable TAVI with cerebral protection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TAVI: CoreValve® Evolut R™, CoreValve Medtronic</intervention_name>
    <arm_group_label>self-expandable TAVI without cerebral protection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TAVI: CoreValve® Evolut R™, CoreValve Medtronic; Sentinel™ Cerebral Protection Systems</intervention_name>
    <arm_group_label>self-expandable TAVI with cerebral protection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with aortic stenosis and indication for transfemoral aortic valve replacement&#xD;
&#xD;
          -  Freedom of significant stenosis in the area of Truncus brachiocephalicus and left A.&#xD;
             carotis (CT)&#xD;
&#xD;
          -  Necessary vessel diameter of 6.5-10 mm in the area of A. carotis communis sinistra and&#xD;
             9-15 mm in the area of Truncus brachiocephalicus (for delivery of protection system)&#xD;
&#xD;
          -  Anomalies of aortic arch (&quot;bovine arch&quot; variants):&#xD;
&#xD;
               1. Direct outflow of left A. carotis communis out of Truncus brachiocephalicus&#xD;
&#xD;
               2. Conjoint origin of Truncus brachiocephalicus and left A. carotis communis out of&#xD;
                  aortic arch&#xD;
&#xD;
          -  The patient has provided written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Apoplexy/ TIA during the last ½ year&#xD;
&#xD;
          -  Severe carotid stenosis (&gt;70%)&#xD;
&#xD;
          -  Symptomatic or asymptomatic carotid stenosis with necessity of TEA or stenting&#xD;
&#xD;
          -  Relevant psychiatric diseases&#xD;
&#xD;
          -  Severe/ relevant visual, auditory or cognitive deficits which impede targeted&#xD;
             anamnesis, neurologic evaluation or consenting.&#xD;
&#xD;
          -  Severe neurodegenerative or progressive neuromuscular disease and state after severe&#xD;
             craniocerebral injury with permanent neurologic sequelae and structural cerebral&#xD;
             diseases&#xD;
&#xD;
          -  Pronounced kinking/ stenosis or calcification in the area of the right A. radialis/&#xD;
             brachialis/ subclavia, which impede implantation of the cerebral protection system&#xD;
&#xD;
          -  Significant stenosis, relevant calcifications, dissections or aneurysmatic alterations&#xD;
             in the area of Truncus brachiocephalicus and/or A. carotis communis sinistra.&#xD;
&#xD;
          -  Contraindications for MRI: among others the presence of a non-MRI-compatible pacemaker&#xD;
             or defibrillator, metal implants in the area to be evaluated, metal fragments in the&#xD;
             craniocerebral area, allergies, claustrophobia.&#xD;
&#xD;
          -  Vessel alterations which impede among others the introduction of a 6 French sheath:&#xD;
&#xD;
               1. Inadequate perfusion in the area of the right upper extremity (pathologic Allen´s&#xD;
                  test, vessel obstructions, peripheral vascular disease)&#xD;
&#xD;
               2. Hemodialysis shunt, grafts, or arteriovenous fistulas in the area of right upper&#xD;
                  extremity&#xD;
&#xD;
          -  Acute myocardial infarction ≤ 1 month prior to the planned procedure&#xD;
&#xD;
          -  Every contraindication for the execution of a transfemoral TAVI&#xD;
&#xD;
          -  Aortic annulus &lt;19 or &gt;29 mm&#xD;
&#xD;
          -  Combined aortic vitium with predominant insufficiency.&#xD;
&#xD;
          -  Severly reduced leftventricular function ≤ 20%&#xD;
&#xD;
          -  Patients who are planned for a hybrid procedure (e.g. conventional operation and TAVI&#xD;
             or simultaneous coronary intervention at coronary artery disease needing intervention)&#xD;
             14 days prior to the planned study procedure&#xD;
&#xD;
          -  Intracardiac thrombus, hematoma, tumor or vegetations confirmed by echocardiography&#xD;
&#xD;
          -  Endocarditis&#xD;
&#xD;
          -  Planned concomitant procedure for atrial fibrillation (operative or via catheter&#xD;
             ablation) during the follow up phase&#xD;
&#xD;
          -  Need for emergency procedure&#xD;
&#xD;
          -  Chronic drug-, medication or alcohol abuse&#xD;
&#xD;
          -  Consuming disease&#xD;
&#xD;
          -  Life expectancy &lt; 1 year&#xD;
&#xD;
          -  Dialysis dependency&#xD;
&#xD;
          -  Patient with legal incapacity, who is not able to understand the essence, meaning and&#xD;
             consequences of the study&#xD;
&#xD;
          -  Participation in other interventional clinical trials in the month of study start or&#xD;
             planned participation during the participation of this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stephanie Voss, Dr.</last_name>
    <phone>0049 89 1218 0</phone>
    <email>VossS@dhm.mhn.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Muenchen, Klinik für Herz- und Gefäßchirurgie</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Voss, Dr.</last_name>
      <phone>00498912180</phone>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 6, 2016</study_first_submitted>
  <study_first_submitted_qc>September 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2016</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aortic stenosis, transcatheter aortic valve replacement, stroke, ischemic infarction, cerebral embolic protection device</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

